New Published Study Finds an Innovative Toothpaste May Be the First To Show Significant Improvements In Patients Suffering From Gum Disease affecting 65 Million Americans Share Article As Scientists Link COVID-19 to Gum Disease, the Study Shows LivFresh Toothpaste Significantly Reduces Gum Bleeding, Gum Inflammation, and Gum Pocket Depths in Patients with Periodontitis, the Most Severe Form of Gum Disease LivFresh represents a groundbreaking therapy in the treatment of periodontal disease. This is the first double-blind clinical study for a toothpaste to report significant reductions in gingival bleeding and pocket depths,” said Dr. Petra Wilder-Smith, a leading US expert in the study oral medicine.